Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atrasentan low dose group · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group A - Placebo QD | PLACEBO_COMPARATOR | - |
| Group B - Low dose Atrasentan QD | ACTIVE_COMPARATOR | - |
| Group C - High dose Atrasentan QD | ACTIVE_COMPARATOR | - |
| ABT-627, Low dose | EXPERIMENTAL | - |
| ABT-627, High dose | EXPERIMENTAL | - |
| ABT-627, Placebo | PLACEBO_COMPARATOR | - |
| A | ACTIVE_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| C | ACTIVE_COMPARATOR | - |
| D | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Atrasentan | DRUG | Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period. |
| Placebo | DRUG | Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period. |
| Atrasentan low dose group | DRUG | Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period. |
| Atrasentan high dose group | DRUG | Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period. |
| Atrasentan placebo group | DRUG | Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period. |
| Placebo for Atrasentan 0.2 mg/mL solution | DRUG | 10 mL oral solution, daily, 8 weeks |
| 0.25 mg Atrasentan QD | DRUG | 10 mL oral solution, daily, 8 weeks |
| 0.75 mg Atrasentan QD | DRUG | 10 mL oral solution, daily, 8 weeks |
| 1.75 mg Atrasentan QD | DRUG | 10 mL oral solution, daily, 8 weeks |
Inclusion Criteria: 1. Subject is greater than or equal to 18 years old. 2. Subject has type 2 diabetes and has been treated with at least one anti-hyperglycemic medication within the 12 months prior to the Screening Period. 3. Subject is currently receiving an angiotensin converting enzyme inhibit...
Top 20 of 25 competitors
Atrasentan is an investigational small molecule being developed for chronic kidney disease and nephropathy, specifically diabetic nephropathy. It is studied for its effect on reducing albuminuria in patients with type 2 diabetic nephropathy who are treated with renin-angiotensin system inhibitors.
Atrasentan is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The drug is currently in Phase 2 clinical development for chronic kidney disease and nephropathy.
Atrasentan is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Four Phase 2 clinical trials have been completed, with no active trials currently ongoing.
Atrasentan has completed four Phase 2 clinical trials. These include NCT00920764, NCT01356849, NCT01399580, and NCT01424319. All trials focused on chronic kidney disease and diabetic nephropathy, with a total enrollment of 347 participants across the United States, Canada, Puerto Rico, Taiwan, and Japan.
Atrasentan is also known by the code name ABT-627. It is an investigational small molecule being studied for chronic kidney disease and nephropathy. The drug is in Phase 2 development and has completed four clinical trials.